Pediatric Nephrology

, Volume 25, Issue 10, pp 2021–2034

When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes


DOI: 10.1007/s00467-010-1498-x

Cite this article as:
Lemley, K.V. Pediatr Nephrol (2010) 25: 2021. doi:10.1007/s00467-010-1498-x


Angiotensin converting enzyme inhibitors (ACEI) and angiotensin 2 receptor blockers (ARB) have become a mainstay of adjunctive therapy for the prevention and amelioration of diabetic nephropathy. Although ACEI were shown over 20 years ago to slow the rate of loss of renal function in diabetic subjects with decreased renal function, the question of how early in the course of diabetes to introduce them remains unresolved. Recent studies suggest that very early initiation of ACEI/ARB therapy may not have demonstrable beneficial effects even over a period of years.


AlbuminuriaNephropathyProgressionSurrogate endpoint

Copyright information

© IPNA 2010

Authors and Affiliations

  1. 1.Division of Nephrology, MS#40Childrens Hospital Los AngelesLos AngelesUSA